Teprotumumab Restarts Clinical Development in New Indication

Teprotumumab Restarts Clinical Development in New Indication

Company Announcement

  *Teprotumumab (RG1507) to be investigated for new indication
  *River Vision Development Corporation to conduct clinical development under
    a license from Roche

COPENHAGEN, Denmark, June 11, 2013 (GLOBE NEWSWIRE) -- Genmab A/S
(Copenhagen:GEN) announced today that teprotumumab (RG1507), an antibody
developed by Genmab under our collaboration with Roche, will restart clinical
development in a Phase 2 study in patients with active thyroid eye disease.
Clinical development will be conducted by River Vision Development
Corporation, who licensed teprotumumab from Roche.

"In drug development, it's often possible to take what was learned about a
product in its initial development and apply it to new indications. We are
pleased that River Vision will resume clinical development of teprotumumab for
the potential treatment of ophthalmic conditions," said Jan van de Winkel,
Ph.D., Chief Executive Officer.

Under our collaboration with Roche, Genmab will receive milestones as well as
royalty payments on successful products.

River Vision Development Corporation is a private company focused on

Today's news does not affect Genmab's financial guidance for 2013.

About Teprotumumab

Teprotumumab is a fully human antibody that targets the Insulin-like Growth
Factor-1 Receptor (IGF-1R) which is a well validated target. Teprotumumab was
previously investigated in various cancer indications.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future
product candidates. Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies. For more
information visit www.genmab.com.


Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to
the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack of
protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion of these
risks, please refer to the risk management sections in Genmab's most recent
financial reports, which are available on www.genmab.com. Genmab does not
undertake any obligation to update or revise forward looking statements in
this Company Announcement nor to confirm such statements in relation to actual
results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab(r); the
Y-shaped Genmab logo(r); the DuoBody(tm) logo; HuMax(r); HuMax-CD20(r);
DuoBody(r), HexaBodyTM and UniBody(r). Arzerra(r) is a trademark of

Company Announcement no. 28
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Press spacebar to pause and continue. Press esc to stop.